Hims & Hers, Novo End Dispute and Announce Collaboration on Wegovy and Ozempic

‘This agreement with Hims & Hers is a meaningful win for patients in the United States,’ the Novo Nordisk president said.

Boxes of Wegovy made by Novo Nordisk at a pharmacy in London, on March 8, 2024. Hollie Adams/Reuters

Novo Nordisk and telehealth company Hims & Hers have ended their dispute over weight loss medications, the companies said on March 9 as they announced a new partnership.

Novo is dropping a patent infringement lawsuit against Hims & Hers, the Denmark-based pharmaceutical company said in a statement. And Novo’s weight loss medications—Ozempic and Wegovy, both approved by the Food and Drug Administration—will be offered through Hims & Hers starting later this month under a new agreement between the firms.